On July 10, the Centers for Medicare & Medicaid Services (CMS) released its Calendar Year (CY) 2025 Medicare Physician Fee Schedule (PFS) proposed rule, which includes proposals related to Medicare physician payment and the Quality Payment Program (QPP). The proposed rule has a 60-day comment period. Final regulations will be issued on or around Nov. 1 and, unless otherwise noted, policies will be effective on Jan. 1, 2025.
Among others, the ACR will provide comments on the following provisions.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
Fee Schedule Provisions
Physician Reimbursement
- The 2025 proposed conversion factor (CF) is $32.3562. This represents a 2.8% decrease from the 2024 CF of $33.2875.
- The change to the PFS conversion factor reflects the expiration of the 2.93% statutory payment increase for CY 2024; a 0.00% conversion factor update under the Medicare Access & Children’s Health Insurance Program Reauthorization Act; and a .05% budget-neutrality adjustment.
- The overall reimbursement for rheumatological services is projected to remain flat compared with 2024.
Non-chemotherapy Administration
ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
- The CMS is proposing clarification to Medicare Administrative Contractors (MACs) regarding the administration of infusion of certain types of drugs and biologics that can be considered complex and may be appropriately reported using chemotherapy administration CPT codes 96401–96549. This clarification will also provide complex clinical characteristics for the MACs to consider as criteria when determining payment of claims for these services.
Part B and Part D Drugs
- The CMS is proposing to implement requirements under the Inflation Reduction Act under which drug manufacturers must pay inflation rebates if they raise the price of certain Part B and Part D drugs by more than the rate of inflation.
- The CMS is proposing a host of methodological changes related to the calculation of rebates for impacted drugs.
Telemedicine
- The CMS is not proposing to extend the geographic location telemedicine flexibilities that originated during the COVID-19 pandemic and were extended through 2024 by Congress. Starting Jan. 1, 2025, telemedicine originating-site specifications would limit patient location to certain rural and underserved areas. Several bills under consideration in Congress would extend or make telemedicine flexibilities permanent.
- The CMS is proposing to permanently reimburse for two-way, real-time audio-only communication to satisfy the requirement for an interactive telecommunications system, when appropriate.
G2211
- The CMS is proposing to pay for G2211 on claims that use modifier -25 to report a Medicare Annual Wellness Visit, vaccine administration or Medicare Part B preventive service at the same encounter as an office/outpatient evaluation and management (E/M) service.
Quality Payment Program